LBA56Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

T Q G Eisen, E Frangou, B Smith,A Ritchie, R S Kaplan, B Oza,I D Davis,M R Stockler, L Albiges,B Escudier,J M G Larkin,A Bex,S Joniau, B W Hancock, G G Hermann, J Bellmunt, E Hodgkinson, P Hanlon,M K B Parmar,A M Meade

ANNALS OF ONCOLOGY(2019)

引用 11|浏览43
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要